Intestinal Disease Education and Awareness Society IDEAS -
AbbVie ($ABBV) has made meds for inflammatory gastrointestinal ills a major theme of its deal-making activities this week. The North Chicago, IL-based drug giant and Belgium’s Galapagos ($GLPG) have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn’s disease. Galapagos plans to fund and launch a midstage study of the compound, […]
The post AbbVie, Galapagos extend JAK1 pact into Crohn’s Disease appeared first on Intestinal Disease Education and Awareness Society IDEAS.